Two New Uscom Devices for China

Uscom has completed the development of two new specialised cardiovascular monitors, the “USCOM O2” and the “USCOM Basic”. The development of these two new monitors creates for Uscom a three-tier range of Uscom haemodynamic monitors for sale into China. Uscom is required to obtain regulatory approval of the China National Medical Products Administration (NMPA) for the two new specialised cardiovascular monitors prior to the commencement of sales. The NMPA process involves 9 steps including document writing, collection, translation, review and product testing, and is estimated to take 12 months for approval, if milestones are achieved according to guidelines. The USCOM 1A is an advanced haemodynamic monitor which can be used to diagnose and manage sepsis, heart failure, hypertension, and fluid, inotrope and vasoactive administration in adults, children and neonates. The new “USCOM O2” is the high end of the Uscom technology range and includes direct measurement of blood oxygen saturation generating beat to beat measures of oxygen delivery, a complex and critical measure of cardiovascular performance. The new “USCOM Basic” is a defeatured device which will be marketed competitively against lower functioning technologies in price-sensitive tenders. These new monitors will be marketed through Uscom China’s current Chinese distribution network.